International Journal of Medical Science and Clinical Research Studies

ISSN (print): 2767-8326, ISSN (online): 2767-8342

Volume 04 Issue 12 December 2024

Page No: 2478-2483

DOI: https://doi.org/10.47191/ijmscrs/v4-i12-51, Impact Factor: 7.949

BRASH Syndrome: A Critical Intersection of Bradycardia, Renal Failure, AV-Node Blockade, Shock, and Hyperkalemia in Clinical Practice

Donaldo Emiliano Silva López[1], Andres Gerardo Herrera Jimenez[2], Jesús Benjamín Díaz Sánchez[3], Maria Fernanda Mireles Ortega[4], Isidro Fabián Martínez Valeriano[3], María Guadalupe Gómez Moreno[5]

[1]Tecnológico de Monterrey Campus Monterrey
[2]Universidad Cuauhtémoc Aguascalientes. Aguascalientes., México.
[3]Universidad autónoma de Aguascalientes, Aguascalienes, Mexico
[4]Universidad Autonoma de Coahuila. Coahuila. Mexico.
[5]Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, México.

ABSTRACT

BRASH syndrome is an underrecognized yet potentially life-threatening clinical entity characterized by the interplay of bradycardia, renal failure, AV-node blockade, shock, and hyperkalemia. This syndrome represents a complex feedback loop where the synergistic effects of hyperkalemia and atrioventricular nodal blocking agents precipitate severe bradycardia, exacerbating renal perfusion and resulting in acute kidney injury. This further amplifies hyperkalemia, perpetuating a vicious cycle that can culminate in cardiogenic shock and multiorgan dysfunction.

Despite its significance, BRASH syndrome is often misdiagnosed as isolated hyperkalemia or primary heart block, leading to delays in appropriate management. Early recognition and a systematic approach to its pathophysiology are essential for targeted treatment. The present review synthesizes current knowledge on the pathogenesis, diagnostic criteria, and evidence-based management strategies for BRASH syndrome, emphasizing the importance of tailored therapeutic interventions to break the cycle of deterioration. Additionally, we discuss emerging insights into its pathophysiology and highlight gaps in the literature requiring further investigation.

KEYWORDS: BRASH syndrome, bradycardia, hyperkalemia, renal failure, AV-node blockade, cardiogenic shock, electrolyte imbalance

ARTICLE DETAILS

Published On:
25 December 2024

Available on:
https://ijmscr.org/

INTRODUCTION:

BRASH syndrome is a recently described yet increasingly recognized clinical syndrome that embodies the intricate interplay of cardiovascular, renal, and metabolic derangements. The term BRASH serves as an acronym for Bradycardia, Renal failure, AV-node blockade, Shock, and Hyperkalemia, encapsulating the core components of this multifaceted syndrome. First reported in the medical literature within the past decade, BRASH syndrome is characterized by a distinctive pathophysiological cascade that can rapidly progress to hemodynamic instability if not promptly addressed.1,2

The central feature of BRASH syndrome lies in the synergistic interaction between hyperkalemia and atrioventricular nodal blocking agents, such as beta-blockers or calcium channel blockers, leading to severe bradycardia. This, in turn, precipitates hypoperfusion and acute kidney injury, which exacerbates hyperkalemia and completes the cycle. The resulting metabolic and hemodynamic disturbances often masquerade as isolated or unrelated clinical conditions, posing a diagnostic challenge for healthcare providers.2,3

Understanding the pathogenesis of BRASH syndrome requires a comprehensive appreciation of the bidirectional relationship between cardiac and renal function. In this syndrome, renal failure reduces potassium excretion, while AV-node blocking agents potentiate the effects of hyperkalemia on the conduction system. Concurrently, the profound bradycardia reduces cardiac output, worsening renal perfusion and perpetuating a cycle of progressive deterioration.3,4

Despite its distinct clinical profile, BRASH syndrome remains underrecognized, often mistaken for isolated hyperkalemia, primary bradyarrhythmias, or decompensated heart failure. This diagnostic ambiguity underscores the need for heightened clinical awareness and a structured diagnostic approach. Early identification and interruption of the pathogenic cycle through judicious management of hyperkalemia, withdrawal of AV-node blocking agents, and hemodynamic stabilization are critical to improving patient outcomes.3,4

This article aims to provide a comprehensive review of BRASH syndrome, outlining its pathophysiological basis, diagnostic considerations, and therapeutic approaches. By elucidating the complexities of this syndrome, we hope to enhance clinical recognition and optimize management strategies, ultimately reducing morbidity and mortality associated with this emergent condition.4,5

EPIDEMIOLOGY

The epidemiology of BRASH syndrome remains poorly defined, largely due to its relatively recent identification as a clinical entity and frequent misclassification under other overlapping conditions such as isolated hyperkalemia, bradyarrhythmias, or acute kidney injury. Available data are primarily derived from case reports and small case series, which provide valuable insights but lack the statistical power to establish prevalence or incidence rates. Nevertheless, emerging evidence suggests that BRASH syndrome may be more common than currently appreciated, particularly among older adults with significant comorbidities.5

The syndrome predominantly affects individuals with predisposing factors such as chronic kidney disease (CKD), heart failure, or concurrent use of atrioventricular nodal blocking agents like beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. Patients with CKD are especially vulnerable due to their impaired ability to excrete potassium, making them more susceptible to hyperkalemia. Additionally, the widespread use of AV-node blocking agents for conditions such as atrial fibrillation or hypertension in this population further exacerbates the risk.6

The interplay between hyperkalemia and bradycardia is a hallmark of BRASH syndrome, and retrospective analyses of hyperkalemia-related admissions suggest that a significant proportion of these patients may meet diagnostic criteria for BRASH syndrome. However, the lack of standardized diagnostic guidelines and the multifactorial nature of its presentation often hinder its recognition in clinical practice.7

Epidemiological patterns indicate a potential predilection for BRASH syndrome in hospitalized patients, particularly those admitted to intensive care units (ICUs). In this setting, the combination of renal dysfunction, electrolyte disturbances, and polypharmacy creates a "perfect storm" for the development of the syndrome. Furthermore, the aging population and increasing prevalence of chronic illnesses are likely to contribute to a rising incidence of BRASH syndrome in the coming decades.7

Future epidemiological studies are essential to elucidate the true burden of BRASH syndrome, identify high-risk populations, and develop predictive tools for its early detection. Standardized diagnostic criteria and large-scale registry data will be pivotal in addressing current knowledge gaps and improving our understanding of this complex condition.7

Clinical Manifestations: BRASH syndrome presents a complex constellation of clinical manifestations that reflect the interplay of its core components: bradycardia, renal failure, AV-node blockade, shock, and hyperkalemia. These manifestations are often subtle in the early stages but can rapidly progress to critical illness if the syndrome is not promptly recognized and managed.7

The hallmark clinical feature of BRASH syndrome is severe bradycardia, which typically manifests as a slow heart rate often out of proportion to the degree of hyperkalemia. Bradycardia in BRASH syndrome results from the synergistic effects of hyperkalemia on cardiac conduction and the pharmacologic action of atrioventricular nodal blocking agents such as beta-blockers, calcium channel blockers, or digoxin. The electrocardiogram (ECG) in these patients frequently reveals sinus bradycardia, junctional rhythms, or advanced atrioventricular blocks.7

Hyperkalemia, a cornerstone of BRASH syndrome, contributes significantly to the clinical picture. Symptoms of hyperkalemia may include muscle weakness, paresthesias, and, in severe cases, life-threatening arrhythmias. The classic ECG changes associated with hyperkalemia, such as peaked T waves, widened QRS complexes, and eventually sine wave patterns, may also be observed. However, these changes are not universal and can sometimes be absent, complicating the diagnosis.8

Renal dysfunction in BRASH syndrome is both a contributor to and a consequence of the syndrome's pathophysiology. Acute kidney injury, characterized by elevated serum creatinine and reduced urine output, is a common finding. Oliguria or anuria may exacerbate hyperkalemia by impairing potassium excretion, perpetuating the vicious cycle of BRASH syndrome.8

Patients with BRASH syndrome frequently exhibit signs of hemodynamic instability, including hypotension and shock. These manifestations arise from the combined effects of bradycardia-induced reduced cardiac output, hyperkalemia-related myocardial depression, and the underlying renal dysfunction. Clinically, these patients may present with cold, clammy extremities, altered mental status, and evidence of end-organ hypoperfusion, such as lactic acidosis or acute hepatic injury.8

The nonspecific nature of these clinical manifestations often leads to diagnostic delays, as BRASH syndrome may mimic other conditions such as isolated hyperkalemia, decompensated heart failure, or sepsis. A high index of suspicion is essential, particularly in patients with known exposure to AV-node blocking agents and predisposing factors such as chronic kidney disease or recent dehydration.8

The progression of BRASH syndrome varies depending on the underlying etiology and the timeliness of intervention. In the absence of appropriate treatment, the syndrome can escalate rapidly, leading to severe metabolic derangements, multiorgan failure, and death. Conversely, early recognition and targeted management can result in rapid clinical improvement, emphasizing the importance of understanding its clinical manifestations in guiding diagnosis and treatment.8

DIAGNOSTIC APPROACH

Diagnosing BRASH syndrome requires a high index of clinical suspicion and a systematic approach to identify its hallmark features: bradycardia, renal dysfunction, hyperkalemia, and recent or ongoing exposure to atrioventricular nodal blocking agents. Due to the syndrome's overlapping presentation with other conditions, clinicians must integrate patient history, clinical findings, laboratory data, and electrocardiographic evidence to establish the diagnosis.8

The cornerstone of diagnosis lies in recognizing the cyclical pathophysiology of BRASH syndrome, where hyperkalemia exacerbates the effects of AV-node blockers, leading to profound bradycardia and subsequent renal hypoperfusion. This vicious cycle necessitates careful evaluation of the patient's medication history, including beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, or any agents that could impair renal function or potentiate hyperkalemia. Recent changes in drug dosages, initiation of new medications, or concurrent dehydration often serve as critical diagnostic clues.8

Electrocardiography (ECG) is pivotal in the diagnostic process, as it provides immediate insights into the patient's cardiac conduction status. Findings typically include sinus bradycardia, junctional rhythms, or varying degrees of atrioventricular block. In addition to bradycardia, ECG changes suggestive of hyperkalemia, such as peaked T waves, prolonged PR intervals, widened QRS complexes, or a sine wave pattern in severe cases, further corroborate the diagnosis. However, it is essential to note that ECG changes may not correlate directly with serum potassium levels, necessitating additional laboratory confirmation.9

Laboratory evaluation plays a central role in diagnosing BRASH syndrome. Key investigations include serum electrolytes, particularly potassium levels, renal function tests such as serum creatinine and blood urea nitrogen (BUN), and markers of acid-base status like arterial blood gases (ABG) and lactate. Elevated potassium levels in the setting of acute or worsening renal dysfunction strongly support the diagnosis, especially when accompanied by bradycardia and a relevant medication history.9

Other diagnostic considerations include excluding alternative causes of bradycardia or hyperkalemia, such as primary sinoatrial or atrioventricular nodal dysfunction, adrenal insufficiency, or acute coronary syndromes. Point-of-care ultrasonography (POCUS) may aid in assessing volume status and cardiac function, providing additional context for the patient's hemodynamic state.9

In cases where the diagnosis remains uncertain, a trial of treatment targeting the components of BRASH syndrome—such as discontinuing AV-node blocking agents, correcting hyperkalemia, and supporting renal function—can provide both therapeutic and diagnostic clarity. Rapid improvement in clinical and laboratory parameters following these interventions further supports the diagnosis of BRASH syndrome.10

Treatment

The pathophysiology involves a complex interplay between hyperkalemia, bradycardia, and AV block, which often leads to hemodynamic instability and renal impairment. Treatment of BRASH syndrome must be prompt and tailored to the underlying etiologies. The management approach should be multidisciplinary, involving the correction of electrolyte imbalances, hemodynamic stabilization, and optimization of renal function.11

Initial Stabilization

The first step in treating BRASH syndrome is the stabilization of the patient's vital signs. This includes ensuring a patent airway, supporting breathing if necessary, and establishing intravenous access for fluid resuscitation. In severe cases of shock, the administration of vasopressors such as norepinephrine may be required to support systemic perfusion. The goal is to maintain adequate blood pressure and perfusion to vital organs, particularly the kidneys, which are highly vulnerable in this syndrome.11

Management of Hyperkalemia

One of the most critical components of BRASH syndrome is hyperkalemia, which exacerbates the bradycardia and AV block seen in these patients. Treatment should focus on rapidly lowering potassium levels to prevent life-threatening arrhythmias. The initial steps include:

- **Calcium gluconate** or **calcium chloride**: These agents stabilize the myocardial cell membrane and counteract the toxic effects of hyperkalemia on cardiac conduction. Calcium is typically administered intravenously in doses of 1–2 grams over 5–10 minutes, monitoring for any signs of extravasation or other adverse effects.11
- **Sodium bicarbonate**: In cases of acidotic patients, sodium bicarbonate can help shift potassium back

into the cells. It is typically administered intravenously in doses of 50-100 mEq, depending on the severity of acidosis and potassium levels.11

- **Insulin and glucose**: A combination of 10 units of regular insulin along with 25–50 grams of glucose (given intravenously) is frequently used to promote the intracellular uptake of potassium. This treatment should be followed by close monitoring of blood glucose levels to prevent hypoglycemia.11
- **Beta-2 agonists**: In some cases, nebulized **albuterol** (salbutamol) can be used to facilitate the shift of potassium into cells, although its effect is typically mild compared to the more direct approaches of insulin or sodium bicarbonate.11
- **Diuretics**: **Furosemide** may be administered to enhance renal potassium excretion if kidney function allows. However, in patients with significant renal failure, this may not be effective.11
- **Dialysis**: In cases of severe hyperkalemia that are refractory to medical management, hemodialysis may be required to remove excess potassium and correct the underlying electrolyte imbalance.12

Bradycardia and AV Block Management

Bradycardia and AV block are characteristic features of BRASH syndrome, often exacerbated by hyperkalemia. Once hyperkalemia has been managed, it is essential to address the conduction abnormalities:

- **Atropine**: If the patient remains symptomatic with bradycardia, atropine (1 mg intravenously) can be administered. This muscarinic antagonist inhibits parasympathetic tone and can increase heart rate. However, atropine may be less effective in cases with significant AV block or those related to hyperkalemia.12
- **Temporary pacing**: If bradycardia and AV block persist, the use of transcutaneous or transvenous pacing should be considered. This intervention is particularly important if the bradycardia is symptomatic or if the patient is in a high-degree AV block, which may impair cardiac output and increase the risk of further hemodynamic deterioration.12

Renal Management

Renal failure is a significant concern in BRASH syndrome and often exacerbates the severity of hyperkalemia and other electrolyte abnormalities. The management of renal dysfunction focuses on preventing further injury and optimizing renal perfusion:

- **Hydration**: Adequate intravenous fluid resuscitation is essential to ensure proper renal perfusion and to prevent prerenal azotemia. Normal saline is typically preferred unless there is concern for fluid overload.12
- **Renal replacement therapy**: In cases of advanced renal failure or oliguria, **hemodialysis** or **peritoneal dialysis**may be required to remove excess potassium, correct metabolic acidosis, and improve renal function. The decision to initiate dialysis should be based on the severity of kidney dysfunction, potassium levels, and the patient's overall clinical condition.13

Addressing Contributing Factors

Since BRASH syndrome is often triggered by medications such as **renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors)**, **beta-blockers**, or **calcium channel blockers**, a thorough review of the patient’s medication regimen is crucial. These medications may need to be temporarily withheld or replaced with alternative therapies to avoid further exacerbation of the syndrome.13

- **Discontinuation of RAAS inhibitors**: Angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), and direct renin inhibitors can exacerbate hyperkalemia, particularly in the setting of kidney dysfunction. These medications should be discontinued immediately and alternative antihypertensive agents considered.13
- **Beta-blockers**: Beta-blockers, especially non-selective ones, can worsen bradycardia and AV block. They should be discontinued if they are contributing to the clinical picture and replaced with agents like **calcium channel blockers** or **vasodilators**.
- **Monitoring for drug interactions**: If the patient is on medications such as **digoxin**, which can also contribute to bradycardia and hyperkalemia, the levels should be checked, and adjustments should be made as necessary.14

Throughout the treatment process, patients with BRASH syndrome require continuous monitoring of vital signs, electrolyte levels (particularly potassium and calcium), and renal function. Electrocardiograms (ECGs) should be performed regularly to assess for the resolution of AV block and bradycardia. Close monitoring of urine output, renal biomarkers (creatinine, BUN), and fluid balance is essential to evaluate renal recovery and the need for further dialysis.15

CONCLUSION

In conclusion, the management of BRASH syndrome is complex and requires rapid intervention to address the electrolyte disturbances, bradycardia, and renal failure that characterize the condition. The primary goals are the stabilization of potassium levels, the correction of bradycardia and AV block, and the optimization of renal function. The treatment strategy should be individualized, taking into account the patient's underlying comorbidities and response to therapy, with a strong focus on preventing progression to more severe complications such as refractory shock or multi-organ failure.

In conclusion, BRASH syndrome represents a complex, multifaceted clinical condition characterized by the simultaneous presence of bradycardia, renal failure, atrioventricular (AV) block, shock, and hyperkalemia. This syndrome, while rare, often emerges in patients with underlying kidney dysfunction and is frequently exacerbated by pharmacologic agents such as renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, and calcium channel blockers. The pathophysiology of BRASH syndrome underscores the critical interplay between electrolyte disturbances, cardiac conduction abnormalities, and renal impairment, which collectively lead to hemodynamic instability and heightened mortality risk if not promptly addressed.

The management of BRASH syndrome requires a rapid, systematic approach that prioritizes the stabilization of vital signs, correction of hyperkalemia, and reversion of bradycardia and AV block. Early identification of the syndrome and its underlying etiologies is paramount, as timely intervention can significantly improve patient outcomes. The cornerstone of treatment involves the administration of calcium salts, sodium bicarbonate, insulin with glucose, and, if necessary, beta-agonists or hemodialysis to address the hyperkalemia and prevent arrhythmias. Additionally, temporary pacing may be required to manage severe bradycardia or high-degree AV block that does not resolve with medical therapy.

Given the often multifactorial nature of BRASH syndrome, a comprehensive approach that includes medication review, electrolyte management, and renal support is crucial to achieving optimal outcomes. The discontinuation of contributing medications, such as RAAS inhibitors and beta-blockers, is necessary to prevent further exacerbation of hyperkalemia and cardiac conduction abnormalities. Close monitoring of renal function, fluid balance, and electrolytes, coupled with ongoing adjustments to treatment regimens, is essential to preventing complications like refractory shock and multi-organ failure.

Ultimately, while BRASH syndrome presents a significant clinical challenge, with a high degree of clinical suspicion, prompt recognition, and appropriate management, most patients can achieve stabilization. However, the complexity of the syndrome underscores the need for a personalized, multidisciplinary approach to care. Further research into the pathophysiological mechanisms and treatment strategies for BRASH syndrome will be instrumental in refining management protocols and improving long-term outcomes for affected patients.

REFERENCES

I. Farkas JD, Long B, Koyfman A, Menson K. BRASH Syndrome: Bradycardia, Renal Failure, AV Blockade, Shock, and Hyperkalemia. J Emerg Med. 2020 Aug;59(2):216–23.

II. Schnaubelt S, Roeggla M, Spiel AO, Schukro C, Domanovits H. The BRASH syndrome: an interaction of bradycardia, renal failure, AV block, shock and hyperkalemia. Intern Emerg Med. 2021 Mar;16(2):509–11.

III. Halli-Tierney A, Scarbrough C, Carroll DG. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019 Jul 1;100(1):32–8.

IV. Ravioli S, Woitok BK, Lindner G. BRASH syndrome – fact or fiction? A first analysis of the prevalence and relevance of a newly describedsyndrome. Eur J Emerg Med. 2021 Apr;28(2):153–5.

V. Lizyness K, Dewald O. BRASH Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: http://www.ncbi.nlm.nih.gov/books/NBK570643/

VI. Sarkar S, Rapista N, Rout A, Chaudhary R. BRASH: Case Report and Review of Literature. Hearts. 2021 Jun 27;2(3):302–6.

VII. Srivastava S, Kemnic T, Hildebrandt KR. BRASH syndrome. BMJ Case Rep. 2020 Feb;13(2):e233825.

VIII. Prabhu V, Hsu E, Lestin S, Soltanianzadeh Y, Hadi S. Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia (BRASH) Syndrome as a Presentation of Coronavirus Disease 2019. Cureus [Internet]. 2020 Apr 24 Available from: https://www.cureus.com/articles/31127-bradycardia-renal-failure-atrioventricular-nodal-blockade-shock-and-hyperkalemia-brash-Syndrome-as-a-presentation-of-coronavirus-disease-2019

IX. Grigorov MV, Belur AD, Otero D, Chaudhary S, Grigorov E, Ghafghazi S. The BRASH syndrome, a synergistic arrhythmia phenomenon. Bayl Univ Med Cent Proc. 2020 Oct 1;33(4):668–70.

X. Wong C, Jaafar M. Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia: An important syndrome to recognize. Turk J Emerg Med. 2021;21(2):86.

XI. Nagamine T. BRASH syndrome associated with angiotensin receptor blocker and SGLT2 inhibitor. Can J Emerg Med [Internet]. 2021 Oct 1; Available from: https://link.springer.com/10.1007/s43678-021- 00213-9

XII. Ata F, yasir M, Javed S, Bilal ABI, Muthanna B, Minhas B, et al. Diagnostic and therapeutic challenges of BRASH syndrome: A case report. Med Case Rep Study Protoc. 2021 Jan;2(1):e0018.

XIII. Diribe N, Le J. Trimethoprim/Sulfamethoxazole-Induced Bradycardia, Renal Failure, AV-Node Blockers, Shock and Hyperkalemia Syndrome. Clin Pract Cases Emerg Med. 2019 Jul 22;3(3):282–5.

XIV. Flores S. Anaphylaxis induced bradycardia, renal failure, AV-nodal blockade, shock, and hyperkalemia: A-BRASH in the emergency department. Am J Emerg Med. 2020 Sep;38(9):1987.e1-1987.e3.

XV. Sattar Y, Bareeqa SB, Rauf H, Ullah W, Alraies MC. Bradycardia, Renal Failure, Atrioventricular-nodal Blocker, Shock, and Hyperkalemia Syndrome Diagnosis and Literature Review. Cureus [Internet]. 2020 Feb 13 Available from: https://www.cureus.com/articles/27877-bradycardia-renal-failure-atrioventricular-nodal-blocker-shock-and-hyperkalemia-syndrome-diagnosis-and-literature-review